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Abstract
Vascular endothelial growth factor (VEGF) is an angiogenic factor with a key role in physiological and pathological 
process. It can be measured in several organic fluids, including serum and plasma samples. The aim of this work was to 
investigate the concentration of serum and plasma VEGF of healthy dogs in order to recommend optimal handling of 
biological samples for accurate measurement of VEGF. Blood samples of thirty dogs were collected into sterile EDTA 
tube for plasma analysis and into clot activator tubes for serum analysis. The tubes were centrifuged within 90 minutes 
of collection at 1400 xg for 10 minutes. VEGF concentration was determined using the quantitative method (ELISA). 
Serum VEGF level was 26.5 + 13.3pg/mL and plasma VEGF was 11.7 + 16.4 pg/mL (p = 0.0003). There was a positive 
correlation between serum VEGF and platelets (r = 0.37, p = 0.03) and a negative correlation between serum VEGF and 
hemoglobin (r = -0.38, p = 0.03) and between plasma VEGF and hemoglobin (r = -0.34, p = 0.06). When compared with 
serum samples it was concluded  that plasma samples could be used as an optimal fluid for measuring VEGF in dogs.
Keywords: Angiogenesis. Growth factor. Organic fluids.
Resumo
O fator de crescimento do endotélio vascular (VEGF) é um fator angiogênico com papel importante em processos 
patológicos e fisiológicos. O VEGF pode ser quantificado em diversos fluidos orgânicos, incluindo amostras de soro 
e plasma. O presente trabalho investigou a concentração do VEGF no soro e no plasma de cães saudáveis a fim de 
recomendar o manejo ótimo de amostras biológicas para a determinação dos níveis do VEGF. Amostras de sangue de 
30 cães saudáveis foram coletadas em tubos estéreis contendo EDTA para análise do plasma e em tubos com ativador 
de coagulação para análise do soro. Os tubos foram centrifugados após 90 minutos da coleta a 1.400 x g por 10 minutos. 
A concentração do VEGF foi determinada com o método quantitativo de ELISA. O nível sérico médio de VEGF foi de 
26,5+13,3pg/mL e o plasmático foi 11,7 + 16.4 pg/mL (p = 0,0003). Houve correlação positiva entre o VEGF do soro com 
as plaquetas (r = 0,37, p = 0,03) e correlação negativa entre o VEGF do soro com hemoglobina (r = -0,38, p = 0,03) e entre 
VEGF do plasma com hemoglobina (r = -0,34, p = 0,06). A comparação dos resultado obtidos nos exames de plasma e 
soro indicou que amostras de plasma podem ser utilizadas como ótimo fluido para quantificação do VEGF de cães 
Palavras-chave: Angiogênese. Fator de crescimento. Fluidos orgânicos.  
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Introduction
Vascular endothelial growth factor is a 
multifunctional cellular factor which can induce 
vascular generation, elevate capillary permeability by 
directly affecting endothelial cells, stimulate mitosis of 
endothelium and play a critical role in the formation 
of a new vascular system and malignant neoplasm 
development (BREKKEN; THORPE, 2001).
VEGF is considered one of the major modulators 
of angiogenesis in a variety of physiological process, 
like wound healing and embryoinic development, 
and plays a role in the physiopathogenesis of diseases 
like diabetic retinopathy, psoriasis and tumor growth 
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(FRANK et al., 1995; CARMELIET et al., 1996; 
FERRARA, 1999). 
Vascular endothelial growth factor represents 
one of the most potent agents promoting tumor 
angiogenesis. VEGF has angiogenic, mitogenic and 
vascular permeability enhancing activity specific for 
endothelial cells, resulting in sprouting of vessels from 
pre-existing microvessels (VEIKKOLA et al., 2000). 
VEGF is involved in development and growth of a 
wide variety of different tumors (HYODO et al., 1998; 
HEFLER et al., 1999). And plays a role in the formation 
of distant metastasis (MAEDA et al., 1996). In several 
types of human cancer the malignant cells produce 
and release soluble VEGF (KOLCH et al., 1995).
VEGF has been measured in serum and plasma of 
tumor patients. VEGF is actively secreted from tumor 
tissue and its soluble form (VEGF165) is detectable in 
the blood compartment (WARTIOVAARA et al., 1998; 
SALGADO et al., 1999). VEGF can be released into 
blood and body fluids in inflammatory or tumorous 
circumstances and has been reported to be elevated in 
serum (FUJIMOTO; SAKAGUCHI; TAMAYA, 1999; 
GARZETTI; CIAVATTINI; LUCARINI, 1999; SANTIN; 
HERMONAT; PARHAM, 1999; QUEIROZ et al., 
2012) and plasma (CLIFFORD et al., 2001; WERGIN 
et al., 2003) from patients with malignant tumors. 
Recently it has been discussed in which blood 
compartment VEGF should be analyzed. In vitro 
experiments have indicated that plasma should 
be used since VEGF in serum is released from 
platelets in a time-dependent manner, making serum 
measurement unreliable (BANKS et al., 1998). It 
was investigated in this study the concentration of 
serum and plasma VEGF of healthy dogs in order to 
recommend optimal handling of biological samples 
for accurate measurement of VEGF. 
Materials and methods
Animals
The present study was approved by the Bioethics 
Committee of the Faculty of Veterinary Medicine 
and Animal Science of Universidade de São Paulo, 
receiving the protocol number 577/2004, and made 
with the free owner’s consent who authorized in 
writing the participation of their animals in the study.
Blood samples were taken from thirty healthy intact 
male dogs presenting to the Veterinary Hospital of 
University of São Paulo/Brazil for elective orchiectomy. 
The mean age of dogs was four years (range from five 
months to eight years), the breed of dogs were four 
Labrador retriever, one Doberman and 25 German 
Shepherd. 
Haematological parameters of all patients were 
recorded. The mean haemoglobin (hb) level was 17.1 
+ 1.3 g/dL. The mean neutrophils count was 7.62 x 103 
+ 1.87 x 103/µL. The mean platelets count was 2.04 x 
105 + 4.5 x 104/µL.
Measument of VEGF
Blood samples of the dogs were collected into 
sterile EDTA tube for plasma analysis and into clot 
activator tubes for serum analysis. The tubes were 
centrifuged within 90 minutes of collection at 1400 xg 
for 10 minutes. The samples were stored at -80ºC until 
assay. VEGF concentration was determined using the 
quantitative method (ELISA kit - Quantikine, R&D 
System) developed to measure the soluble VEGF 
levels (VEGF 121 and VEGF165) in various human 
fluids. The validation of the ELISA test to measure 
canine VEGF using human antibody was previously 
confirmed by Clifford et al. (2001) and Gentillini et 
al. (2005). The concentration values were calculated 
according to the manufacturer’s protocol and obtained 
in picograms per milliliter (pg/mL). 
Statistical analysis
Statistical analysis (SAS Institute, Cary, NC, USA) 
was performed using the ANOVA test and Pearson 
correlation. 
Results
Serum  VEGF  level  was  26.5 + 13.3 pg/mL,  significantly 
higher (p = 0.0003) compared with plasma VEGF, 
11.7 + 16.4 pg/mL. 
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Haematological parameters were within normal 
limits for the specie. There was a significant positive 
correlation between serum VEGF and platelets 
(r = 0.37, p = 0.03). There was a significant negative 
correlation between serum VEGF and hemoglobin 
(r = -0.38, p = 0.03) and between plasma VEGF and 
hemoglobin (r = -0.34, p = 0.06), but no significant. 
Discussion
Vascular endothelial growth factor exists in four 
isoforms resulting from alternative exon splicing of 
its ribonucleic acid (RNA) transcript (HOUCK et al., 
1991, TISCHER et al., 1991). Of these isoforms, only 
VEGF121 and VEGF165 are secreted in soluble form, 
with VEGF165 being predominant soluble isoform 
(HOUCK et al., 1992). 
The main isoforms of canine VEGF are VEGF120, 
VEGF164 and VEGF188. The deduced amino acid se-
quence display only 4.8% changed residues compared 
to the human VEGF sequence (SCHEIDEGGER 
et al., 1999). We investigated the soluble isoform of 
VEGF in serum and plasma of health dogs using a 
quantitative method developed to measure the soluble 
VEGF levels in human fluids because of the structural 
similarity between the two species as mentioned by 
the above authors. Furthermore, the reliability of this 
assay for use in dogs was performed by Clifford et al. 
(2001) and Gentillini et al. (2005).
Serum provides the liquid portion of the blood 
without cells and clotting factors and, therefore, should 
contain proteins and other molecules that represent 
the whole body system. The cells and clotting factors 
must be removed from the blood sample by allowing 
adequate time for a clot to form. Most manufacturers of 
collections systems for serum samples recommend 30-
60 min at room temperature for a clot to form and longer 
if the subject was taking any kind of anticoagulant at 
sample collection (ARZOUMANIAN, 2003).
Serum samples that are allowed to sit less than 30 
min are likely to retain cellular elements and other 
contaminants impacting future analysis. Samples that 
sit longer than 60 min are likely to experience lysis 
of cells in the clot, releasing cellular components not 
usually found in the serum samples (TIMMS et al., 
2007). In this investigation the samples were allowed 
to sit 90 min, which may have caused cell lysis 
increasing serum VEGF when compared with plasma 
VEGF. 
Kusumanto et al. (2003) conducted a study in 
thirteen healthy subjects and found that, in healthy 
people, 58% of VEGF in the bloodstream is the 
fraction of granulocytes. Maloney et al. (1998) 
founded that VEGF was secreted in vitro aggregation 
of platelet-rich plasma induced by thrombin, collagen, 
epinephrine and ADP. Furthemore, sérum VEGF 
levels were increased when compared with plasma. 
Salgado et al. (2001) observed a correlation between 
platelet count and sérum VEGF level in the healthy 
control. In the present investigation it was found a 
positive correlation between serum VEGF and the 
platelet in healthy dogs. These data corroborate with 
hypothesis of several researchers that platelets carriers 
VEGF to the circulating blood.
Plasma does not contain significant amounts of 
VEGF, indicating that VEGF measured from serum 
samples is released from the blood cells during the 
coagulation process. It should, therefore, be noted 
that variations in samples handling may affect the 
blood cell activation and, thus, the release of VEGF 
to serum (WARTIOVAARA et al., 1998). In this study 
the samples serum contained quantities of VEGF 
elevated when compared with plasma. Therefore, 
VEGF may have been released by cells lysis resulting 
from prolonged clotting and platelet activation.
One major stimulus for increased VEGF expression 
is hypoxia (HARRIS, 2002). Dunst et al. (2002) 
have reported an association between anaemia and 
elevated level of plasma VEGF in human patients. In 
the present paper, it was found that, as the quantity of 
hemoglobin was reduced, serum and plasma VEGF 
concentration was increased; suggesting that, even in 
the absence of anemia, the reduction in the amount of 
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hemoglobin can be a stimulus for release of VEGF in 
circulating blood. 
VEGF has been implicated as an angiogenic 
factor in human and dogs with tumors through 
immunohistochemistry or blood concentration in 
serum and plasma samples, therefore, the outcomes 
are controversial. This study investigated VEGF 
concentration in plasma and serum of healthy 
dogs and revealed the plasma as the ideal fluid for 
measuring VEGF. Processing and handling of serum 
can increase VEGF serum concentration. Further 
research should be undertaken comparing VEGF in 
these fluids of cancer patients.
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